Lung & Respiratory Disease Clinical Trials Update: Week 24, 2026

Published June 12, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

This Phase 3 study evaluates a triple combination drug treatment for cystic fibrosis patients aged 12 months and older. It focuses on understanding the long-term safety and effectiveness of this treatment, which may improve lung function and overall quality of life for patients. Although the trial is no longer recruiting, it is active in multiple countries and could provide important information on managing cystic fibrosis in very young children and older patients.

Health Economic Evaluation of Influenza and Pneumococcal Vaccination in COPD Patients

This Phase 4 trial investigates how flu and pneumococcal vaccines affect adults aged 45 to 80 living with Chronic Obstructive Pulmonary Disease (COPD). By studying the impact of these vaccines on disease progression and healthcare use, the research aims to reduce flare-ups and hospital visits for COPD patients. The study is currently recruiting participants across several centers and will follow them for 12 months.

Active Airways for Children and Young People With Asthma

This study explores exercise and asthma education programs for children and teens aged 10 to 17 with asthma. It aims to help young people manage their asthma through physical activity and better knowledge rather than relying solely on medication. Recruiting in the United Kingdom, this study hopes to improve daily health and quality of life for participants through these non-drug approaches.

Interest of in Situ Terlipressin Administration Before the Realisation of Bronchial Biopsy

This Phase 3 trial completed in France tested a new method of using terlipressin during bronchoscopy procedures for lung biopsy. The goal was to reduce bleeding and increase the number of biopsies doctors can safely perform, which may help diagnose lung cancer more accurately. Results from the 130 participants are pending and may influence future biopsy techniques.

Real-time Smoking Cessation Instant Messaging Support Using a Large Language Model (LLM)-Based Chatbot Via "Quit to Win" 2025 (QTW2025)

This study tested a chatbot designed to provide instant messaging support for adults trying to quit smoking. By using a large language model, the chatbot offers personalized advice and encouragement, aiming to make quitting more accessible than traditional methods. Completed in Hong Kong with over 1,000 participants, the results could guide future smoking cessation programs.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.